Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of NTQ5082 in primary IgA nephropathy
CTR20251705Phase 2Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NTQ5082 in IgA nephropathy (IgAN), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jul 2025; status: active.
02
Drugs
NTQ5082
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20251705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251705.